Ipca Laboratories Ltd (IPCALAB) is currently trading at 1,917.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Ipca Laboratories is a fully integrated Indian pharmaceutical company manufacturing and marketing over 350 formulations and about 80 APIs from 18 Indian manufacturing sites, selling products in more than 100 countries with approvals from major regulators including US FDA, MHRA, ANVISA and TGA and a strong legacy in select APIs such as atenolol and chloroquine. Recent operating momentum: management reported domestic formulations growth of roughly 12% in the quarter, export formulations growth of circa 17% in Q3 and consolidated nine‑month revenue up about 8.4% to INR7,258 crore; standalone and consolidated EBITDA margins improved materially year‑on‑year, driven by mix shifts toward higher‑margin branded and promotional businesses. Strategic and product developments: Ipca has re‑entered and expanded its U.S. generic exposure with around 35 US registrations (five commercialized) and reported a combined U.S. run‑rate near INR395 crore in Q3; the company also disclosed five biosimilar candidates with technology transfer underway, signaling a strategic pivot toward higher value biologic development and global commercialization. Capital and integration posture: management says near‑term organic capex is minimal aside from a planned INR50 crore solar project, while the acquisition and integration of Unichem are expected to improve utilisation and margins over the next two to three years, although Unichem’s near‑term EBITDA will remain under pressure until market share recovers in the U.S.

Over the past 52 weeks, Ipca Laboratories Ltd has traded between a low of ₹1,252.95 and a high of ₹1,945.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Ipca Laboratories Ltd has a market capitalization of approximately 48,468.92. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Ipca Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 37.00 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 48,468.92 Cr, Ipca Laboratories Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Ipca Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Ipca Laboratories Ltd is 37.00. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The stock jumped after Ipca reported 21% YoY revenue growth, strong profit growth, margin expansion, and upgraded FY27 revenue and EBITDA margin guidance.

The stock surged after Ipca said the USFDA classified its Ratlam API facility as Voluntary Action Indicated (VAI) in the Establishment Inspection Report, which the company described as minimally acceptable CGMP compliance.

Management reported FY26 consolidated revenue of ₹9,646 crore, up 8% year-on-year.

Ipca reported FY26 revenue of ₹9,646 crore, up 8% year-on-year, and an EBITDA margin of 20.5% versus 19.3% in FY25.